Bedrijfsoverzicht
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company dedicated to the discovery, development, and commercialization of botanical drugs designed to treat patients suffering from inflammatory diseases. The corporation operates within the Healthcare sector and specifically functions in the Biotechnology industry, focusing on the creation of therapeutic solutions for conditions such as ulcerative colitis, atopic dermatitis, and COVID-19 using its Phyto-N platform. The company currently holds a market capitalization of $13.15M, while its annual revenue and total employee count are not available in the provided financial records. The market capitalization figure of $13.15M indicates that Curanex operates as a micro-cap entity with limited public float, suggesting a position in the market where valuation is heavily influenced by early-stage development milestones rather than established cash flows or extensive operational scale.
Financiële gezondheid
The company reported net income of $-435,034 over the trailing twelve months, while revenue, EBITDA, and the gap between revenue and net income figures are not explicitly quantified in the available data. The reported free cash flow stands at $-504,457, which signifies a consumption of cash rather than generation, indicating that the company's financial flexibility is currently constrained by the high capital requirements typical of developmental stage biotechnology firms. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the lack of profitability often found in early-stage companies that have not yet achieved commercial product revenue or have not yet scaled operations to generate positive operating leverage. Regarding the balance sheet, the company holds $108,862 in cash against total debt of $476,452, resulting in a debt-to-equity ratio of 155.99, which illustrates a highly leveraged financial structure where liabilities significantly outweigh equity. Despite the high debt load, the current ratio is 9.37, a metric that suggests strong short-term liquidity as the company possesses substantial current assets relative to its current liabilities. Furthermore, the return on equity is -85.2% and the return on assets is -30.0%, metrics that reveal that management effectiveness, measured by shareholder returns and asset utilization, is currently negative due to the cumulative losses incurred during the developmental phase of the business.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A because the company has negative earnings, which makes traditional earnings-based valuation multiples inapplicable for assessing expected earnings trajectory in the current period. The price-to-book ratio is 35.70, a valuation metric that indicates the market is pricing the company at a significant premium relative to its book value, likely driven by potential future value in the Phyto-N platform rather than current tangible assets. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available due to the lack of positive sales data and EBITDA figures, suggesting that investors must rely on other qualitative factors or non-earnings-based multiples to assess the stock's relative value. The stock has traded between a 52-week high of $9.18 and a 52-week low of $0.26, providing a wide range of price volatility that reflects the speculative nature of developmental biotechnology stocks. The beta value is not available in the provided data, which prevents a direct comparison of the stock's price volatility relative to the broader market index based on historical correlation coefficients.
Growth & Income
Revenue growth and earnings growth rates are not available in the current financial dataset, preventing a direct comparison of whether earnings are growing faster or slower than revenue over the year-over-year period. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available earnings to reinvest into research and development rather than distributing income to shareholders. Because the company is a non-dividend payer, its strategy focuses on reinvesting limited cash reserves into the discovery and commercialization of botanical drugs to drive future growth potential. The overall growth and income profile is characterized by a complete absence of current income distribution and undefined growth rates, highlighting the company's status as a pure-play developmental stage entity reliant on future product approvals to unlock value.